At the 2014 American Society of Hematology annual meeting in San Francisco, Dr. Thomas Kipps, from the Moores Cancer Center of UCSD discusses his recently opened first-in-human clinical trial with a ROR1 antibody.
Take Away Points:
- ROR1 antibodies clinical trials are now open.
- ROR1 may specifically target CLL cancer stem cells thus lowering the risk of relapse.
- Checkpoint inhibitors (PD-1) are also being studied in clinical trials in CLL following the successful outcomes in solid tumor trials and the hope of deeper responses and improved immune function.
In the first part of my interview, Dr. Kipps discusses his recently opened first-in-human trial with a ROR1 antibody. ROR1 is a fetal protein that seems to play a role in primitive cells spreading or metastasizing to form distant to new organs as we develop. It disappears after birth for the most part, except in CLL and in perhaps some other solid tumors where it may play an important role in cancers relapsing and spreading.
It is therefore a perfect target for an antibody with the hope of minimal collateral damage.
Dr. Kipps is working long and hard on a strategy to provide the knock-out punch to our CLL and ROR1 may be that finisher.
Here is the link to Dr. Kipps’ trial with the new ROR1 antibody and here is a link to a CAR-T trial targeting ROR1 at MD Anderson headed up by Dr. Wierda.
In all the excitement about new oral therapies for CLL, it is important to remember the critical role that immune therapy plays means it is likely to be part of any cure.
Below is part 1 of our ASH 2014 interview:
Dr. Brian Koffman 5/3/2015